Expert Interview
Comparing Roche’s emicizumab (ACE910) recent Phase 3 HAVEN 1 and 2 results to Bioverativ’s FDA approved Eloctate and Alprolix in the treatment of Hemophilia
Ticker(s): RHHBY, BIVV, SHPGA hematologist who can go into details of the first line of medication in treating Hemophilia A, and how emicizumab could fit in those treatment plants.
Could you describe your background in treating Hemophilia, your clinical practice, and the first-line of therapy?
Added By: kcmckeeWhat are the patient demographics of this disease? How often do complications and infections develop in patients on chronic treatment, and what are the urgent treatment options in case of a severe hemorrhage caused by an accident in a hemophilia patient?
Added By: kcmckeeEmicizumab shows a 70% to 90% reduction in bleeding according to the Phase 3 data, how significant is this, and how does it compare to the other treatment options available on the market, including Eloctate.
Added By: kcmckee62% of the patients enrolled in HAVEN 1 trial reported 0 bleeds while on treatment with emicizumab. How does this compare to Eloctate, and other treatment options on the market now?
Added By: kcmckeeCan you describe the market landscape in Hemophilia B? How often is Alprolix prescribed, compared to other treatment options?
Added By: kcmckeeIs the dosing frequency an important matter that you and your patients highly consider, and what are the other aspects that are also important in prescribing the treatment? How does emicizumab’s once weekly injection frequency fit in the market landscape?
Added By: kcmckeeHow does emicizumab’s ABR( annual bleeding rate) of 2.9 compare to Eloctate’s 1.6?
Added By: kcmckeeBioverativ is making a new addition to the Hemophilia pipeline with BIVV001 and BIVV002; both drugs in preclinical stage, soon to initiate Phase ½. What is your impression of it? Can it make a big impact in the future treatment of Hemophilia?
Added By: kcmckeeAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
